Holding(s) in Company

RNS Number : 1223V

Allergy Therapeutics PLC

03 July 2009

 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Allergy Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights		X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	Increase in total voting rights issued by the Company	X

3. Full name of person(s) subject to the notification obligation:	FIL Limited
4. Full name of shareholder(s) (if different from 3.):	See attached schedule
5. Date of the transaction and date on which the threshold is crossed or reached:	01 July 2009
6. Date on which issuer notified:	03 July 2009
7. Threshold(s) that is/are crossed or reached:	10%

8. Notified details:
A: Voting rights attached to shares
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights		% of voting rights
			Indirect	Direct	Indirect	Direct	Indirect
GB00B02LCQ05	8,854,410	8,854,410	16,343,693		16,343,693		6.19

B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration date	Exercise/  Conversion  Period	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Exercise  price	Expiration  date	Exercise/ Conversion  period	Number of voting  rights instrument  refers to	% of voting rights
					Nominal	Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
16,343,693	6.19

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

See attached schedule

Proxy Voting:
10. Name of the proxy holder:	FIL Limited
11. Number of voting rights proxy holder will cease to hold:	7,489,283
12. Date on which proxy holder will cease to hold voting rights:	01 July 2009

13. Additional information:	Increase in total voting rights issued by the Company
14. Contact name:	Amanda Chana
15. Contact telephone number:	[e-mail]

FIL

 

Issuer Name:                                              ALLERGY THERAPEUTICS LTD

 

Current ownership percentage:                          6.19%

Total Shares Held:                                       16,343,693

Issued Share Capital:                                  263,996,551

 

 

SHARES HELD	NOMINEE	MANAGEMENT COMPANY
128,417	JPMORGAN, BOURNEMOUTH	FIL
16,215,276	JPMORGAN, BOURNEMOUTH	FISL

 

FIL Limited (FIL) is the parent holding company for various direct and indirect subsidiaries, including FIL Fund Management Limited (FFML), FIL Investment Services Ltd (FISL), FIL Gestion (FIGEST), FIL Asset Management (Korea) Limited (FIAKL), FIL Investments Management (Hong Kong) Limited (FIMHK), FIL Pension Management (FPM), Fidelity Investments Japan (FIJ) and FIL Investments International (FII), Investment managers for various non-US investment companies and institutional clients.

 

 

END

 

 

HOLUOSSRKBRBRAR